Tumor vaccines and cellular immunotherapies

John Nemunaitis, Neil Senzer, Leah Plato

Abstract

A recent meta-analysis (using random effects modeling) of patients with advanced non-small cell lung cancer (NSCLC) comprising 6,756 patients enrolled in 18 randomized controlled trials [Dammeijer et al. (1)] reported a clinical advantage for “tumor vaccines” and “cellular immunotherapies”.